# DNA X, Inc.: financial statements, quarterly

SONM · Nasdaq · CIK 1178697 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sonm.md) · [Financials](/companies/sonm/financials.md) · [Filings](/companies/sonm/filings.md) · [Insiders](/companies/sonm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sonm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [27.6](/filings/0001493152-24-045139.md) | [13.4 d](/filings/0001641172-25-001720.md) | [9.1](/filings/0001641172-25-009749.md) | [11.5](/filings/0001641172-25-022821.md) | [15.0](/filings/0001493152-25-020310.md) | [15.3 d](/filings/0001641172-25-001720.md) | [16.7](/filings/0001641172-25-009749.md) | [11.2](/filings/0001641172-25-022821.md) | [16.2](/filings/0001493152-25-020310.md) | not reported | not reported | not reported |
| Cost of revenue | $m | [22.0](/filings/0001493152-24-045139.md) | [8.3 d](/filings/0001641172-25-001720.md) | [13.9](/filings/0001641172-25-009749.md) | [8.5](/filings/0001641172-25-022821.md) | [10.8](/filings/0001493152-25-020310.md) | [15.2 d](/filings/0001641172-25-001720.md) | [8.4](/filings/0001641172-25-009749.md) | [10.3](/filings/0001641172-25-022821.md) | [14.4](/filings/0001493152-25-020310.md) | not reported | not reported | not reported |
| Gross profit | $m | [5.6](/filings/0001493152-24-045139.md) | [5.1 d](/filings/0001641172-25-001720.md) | [2.9](/filings/0001641172-25-009749.md) | [3.0](/filings/0001641172-25-022821.md) | [4.2](/filings/0001493152-25-020310.md) | [(0.2) d](/filings/0001641172-25-001720.md) | [8.4](/filings/0001641172-25-009749.md) | [0.8](/filings/0001641172-25-022821.md) | [1.8](/filings/0001493152-25-020310.md) | not reported | not reported | not reported |
| Research and development | $m | [0.7](/filings/0001493152-24-045139.md) | [0.9 d](/filings/0001641172-25-001720.md) | [0.5](/filings/0001641172-25-009749.md) | [0.6](/filings/0001641172-25-022821.md) | [0.7](/filings/0001493152-25-020310.md) | [12.5 d](/filings/0001641172-25-001720.md) | [1.6](/filings/0001641172-25-009749.md) | [0.9](/filings/0001641172-25-022821.md) | [0.2](/filings/0001493152-25-020310.md) | not reported | not reported | not reported |
| Operating income | $m | [0.7](/filings/0001493152-24-045139.md) | [(1.3) d](/filings/0001641172-25-001720.md) | [(2.7)](/filings/0001641172-25-009749.md) | [(6.5)](/filings/0001641172-25-022821.md) | [(2.4)](/filings/0001493152-25-020310.md) | [8.4 d](/filings/0001493152-26-016659.md) | [(0.9)](/filings/0001493152-26-024644.md) | [(1.5)](/filings/0001493152-26-039226.md) | [(4.0)](/filings/0001493152-25-020310.md) | [4.7 d](/filings/0001493152-26-016659.md) | [(3.6)](/filings/0001493152-26-024644.md) | [(1.3)](/filings/0001493152-26-039226.md) |
| Interest expense | $m | [0.0 d](/filings/0001493152-23-041079.md) | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001493152-26-024644.md) | [0.2](/filings/0001641172-25-022821.md) | [0.3](/filings/0001493152-25-020310.md) | [0.4 d](/filings/0001493152-26-016659.md) | [0.1](/filings/0001493152-26-024644.md) | not reported |
| Income tax | $m | [0.1](/filings/0001493152-24-045139.md) | [0.1 d](/filings/0001641172-25-001720.md) | [0.1](/filings/0001641172-25-009749.md) | [0.0](/filings/0001641172-25-022821.md) | [0.1](/filings/0001493152-25-020310.md) | [(0.1) d](/filings/0001493152-26-016659.md) | [0.1](/filings/0001493152-26-024644.md) | [0.1](/filings/0001493152-26-039226.md) | [0.1](/filings/0001493152-25-020310.md) | [(1.5) d](/filings/0001493152-26-016659.md) | [2.5](/filings/0001493152-26-024644.md) | [(0.2)](/filings/0001493152-26-039226.md) |
| Net income | $m | [0.5](/filings/0001493152-24-045139.md) | [(1.4) d](/filings/0001641172-25-001720.md) | [(2.9)](/filings/0001641172-25-009749.md) | [(6.6)](/filings/0001641172-25-022821.md) | [(2.5)](/filings/0001493152-25-020310.md) | [(21.6) d](/filings/0001493152-26-016659.md) | [0.5](/filings/0001493152-26-024644.md) | [(7.5)](/filings/0001493152-26-039226.md) | [(4.8)](/filings/0001493152-25-020310.md) | [(8.9) d](/filings/0001493152-26-016659.md) | [6.3](/filings/0001493152-26-024644.md) | [(1.2)](/filings/0001493152-26-039226.md) |
| Diluted EPS | $ per share | [0.12](/filings/0001493152-24-045139.md) | not reported | [(0.65)](/filings/0001641172-25-009749.md) | [(1.41)](/filings/0001641172-25-022821.md) | [(9.32)](/filings/0001493152-25-020310.md) | not reported | [1.41](/filings/0001493152-26-024644.md) | [(14.15)](/filings/0001493152-26-039226.md) | [(4.83)](/filings/0001493152-25-020310.md) | not reported | [5.01](/filings/0001493152-26-024644.md) | [(0.92)](/filings/0001493152-26-039226.md) |
| Basic EPS | $ per share | [0.12](/filings/0001493152-24-045139.md) | not reported | [(0.65)](/filings/0001641172-25-009749.md) | [(1.41)](/filings/0001641172-25-022821.md) | [(9.32)](/filings/0001493152-25-020310.md) | not reported | [1.41](/filings/0001493152-26-024644.md) | [(14.15)](/filings/0001493152-26-039226.md) | [(4.83)](/filings/0001493152-25-020310.md) | not reported | [5.01](/filings/0001493152-26-024644.md) | [(0.92)](/filings/0001493152-26-039226.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.8](/filings/0001493152-23-041079.md) | [9.4](/filings/0001641172-25-001720.md) | [9.3](/filings/0001493152-24-019245.md) | [9.6](/filings/0001493152-24-030969.md) | [9.1](/filings/0001493152-24-045139.md) | [5.3](/filings/0001493152-26-016659.md) | [2.1](/filings/0001641172-25-009749.md) | [2.0](/filings/0001641172-25-022821.md) | [2.1](/filings/0001493152-25-020310.md) | [1.3](/filings/0001493152-26-039226.md) | [1.2](/filings/0001493152-26-024644.md) | [0.9](/filings/0001493152-26-039226.md) |
| Current assets | $m | [47.5](/filings/0001493152-23-041079.md) | [43.8](/filings/0001641172-25-001720.md) | [29.5](/filings/0001493152-24-019245.md) | [32.6](/filings/0001493152-24-030969.md) | [33.9](/filings/0001493152-24-045139.md) | [32.2](/filings/0001493152-26-016659.md) | [26.9](/filings/0001641172-25-009749.md) | [27.1](/filings/0001641172-25-022821.md) | [30.3](/filings/0001493152-25-020310.md) | [28.9](/filings/0001493152-26-039226.md) | [3.3](/filings/0001493152-26-024644.md) | [2.9](/filings/0001493152-26-039226.md) |
| Total assets | $m | [58.6](/filings/0001493152-23-041079.md) | [56.0](/filings/0001641172-25-001720.md) | [42.4](/filings/0001493152-24-019245.md) | [45.9](/filings/0001493152-24-030969.md) | [49.1](/filings/0001493152-24-045139.md) | [39.7](/filings/0001493152-26-016659.md) | [36.0](/filings/0001641172-25-009749.md) | [36.1](/filings/0001641172-25-022821.md) | [40.2](/filings/0001493152-25-020310.md) | [43.9](/filings/0001493152-26-039226.md) | [4.8](/filings/0001493152-26-024644.md) | [4.5](/filings/0001493152-26-039226.md) |
| Current liabilities | $m | [34.0](/filings/0001493152-23-041079.md) | [32.1](/filings/0001641172-25-001720.md) | [21.0](/filings/0001493152-24-019245.md) | [26.9](/filings/0001493152-24-030969.md) | [32.2](/filings/0001493152-24-045139.md) | [43.7](/filings/0001493152-26-016659.md) | [34.7](/filings/0001641172-25-009749.md) | [35.7](/filings/0001641172-25-022821.md) | [38.9](/filings/0001493152-25-020310.md) | [50.6](/filings/0001493152-26-039226.md) | [4.3](/filings/0001493152-26-024644.md) | [5.1](/filings/0001493152-26-039226.md) |
| Total liabilities | $m | [35.5](/filings/0001493152-23-041079.md) | [33.7](/filings/0001641172-25-001720.md) | [22.5](/filings/0001493152-24-019245.md) | [28.4](/filings/0001493152-24-030969.md) | [33.8](/filings/0001493152-24-045139.md) | [45.4](/filings/0001493152-26-016659.md) | [37.0](/filings/0001641172-25-009749.md) | [37.4](/filings/0001641172-25-022821.md) | [40.9](/filings/0001493152-25-020310.md) | [50.6](/filings/0001493152-26-039226.md) | [4.9](/filings/0001493152-26-024644.md) | [5.7](/filings/0001493152-26-039226.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.6](/filings/0001641172-25-009749.md) | [2.9](/filings/0001641172-25-022821.md) | [0.3](/filings/0001493152-25-020310.md) | [5.1](/filings/0001493152-26-016659.md) | [1.1](/filings/0001493152-26-024644.md) | not reported |
| Current portion of debt | $m | [0.0](/filings/0001493152-23-041079.md) | not reported | not reported | not reported | not reported | not reported | [2.3](/filings/0001641172-25-009749.md) | [2.9](/filings/0001641172-25-022821.md) | [4.8](/filings/0001493152-25-020310.md) | [5.1](/filings/0001493152-26-016659.md) | [1.1](/filings/0001493152-26-024644.md) | not reported |
| Shareholders' equity | $m | [23.1](/filings/0001493152-24-045139.md) | [22.4](/filings/0001493152-26-016659.md) | [19.8](/filings/0001641172-25-022821.md) | [17.5](/filings/0001493152-25-020310.md) | [15.3](/filings/0001493152-25-020310.md) | [(5.7)](/filings/0001493152-26-039226.md) | [(1.1)](/filings/0001493152-26-039226.md) | [(1.3)](/filings/0001493152-26-039226.md) | [(0.7)](/filings/0001493152-25-020310.md) | [(8.0)](/filings/0001493152-26-039226.md) | [(1.0)](/filings/0001493152-26-039226.md) | [(1.2)](/filings/0001493152-26-039226.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(304) d](/filings/0001493152-24-045139.md) | [(351) d](/filings/0001641172-25-001720.md) | [(168)](/filings/0001641172-25-009749.md) | [(3,392) d](/filings/0001641172-25-022821.md) | [(417) d](/filings/0001493152-25-020310.md) | [(4,509) d](/filings/0001493152-26-016659.md) | [(9,606)](/filings/0001493152-26-024644.md) | [(4,882) d](/filings/0001493152-26-039226.md) | [(7,034) d](/filings/0001493152-25-020310.md) | [(2,004) d](/filings/0001493152-26-016659.md) | [(3,466)](/filings/0001493152-26-024644.md) | [(2,001) d](/filings/0001493152-26-039226.md) |
| Capital expenditure | $k | [1.0 d](/filings/0001493152-24-045139.md) | [12.0 d](/filings/0001641172-25-001720.md) | [30.0](/filings/0001641172-25-009749.md) | [39.0 d](/filings/0001641172-25-022821.md) | [137 d](/filings/0001493152-25-020310.md) | [8.0 d](/filings/0001493152-26-016659.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.1](/filings/0001493152-23-041079.md) | [41.1](/filings/0001493152-24-019245.md) | [4.5](/filings/0001493152-24-030969.md) | [4.4](/filings/0001493152-24-045139.md) | [4.4](/filings/0001641172-25-009749.md) | [4.7](/filings/0001641172-25-022821.md) | [0.3](/filings/0001493152-25-020310.md) | [0.3](/filings/0001493152-26-024644.md) | [0.5](/filings/0001493152-26-039226.md) | [1.0](/filings/0001493152-25-020310.md) | [1.3](/filings/0001493152-26-024644.md) | [1.4](/filings/0001493152-26-039226.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,488,268 at 2026-08-18, from the cover of the [10-Q filed 2026-08-19](/filings/0001493152-26-039226.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.